Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
01/31/20253:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/23/20254:41PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/22/20256:30AMGlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
01/10/20256:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
01/09/20253:00PMGlobeNewswire Inc.Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)NASDAQ:NTLAIntellia Therapeutics Inc
01/07/20254:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/07/20254:22PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/07/20254:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/07/20254:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/07/20254:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/06/20253:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
01/06/20256:30AMGlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
12/03/20243:01PMGlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
11/25/20246:30AMGlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyNASDAQ:NTLAIntellia Therapeutics Inc
11/18/20246:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
11/16/20249:16AMGlobeNewswire Inc.Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
11/07/20243:05PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
11/07/20246:45AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
11/07/20246:30AMGlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
11/05/20243:01PMGlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
10/31/20246:30AMGlobeNewswire Inc.Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024NASDAQ:NTLAIntellia Therapeutics Inc
10/25/20243:59PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
10/24/20247:01AMGlobeNewswire Inc.Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
10/10/20246:30AMGlobeNewswire Inc.Intellia Therapeutics Announces New Date for Upcoming Investor WebcastNASDAQ:NTLAIntellia Therapeutics Inc
10/07/20246:30AMGlobeNewswire Inc.Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
10/04/20244:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
10/03/20243:01PMGlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
10/01/20246:30AMGlobeNewswire Inc.Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific SessionsNASDAQ:NTLAIntellia Therapeutics Inc
09/12/20246:30AMGlobeNewswire Inc.Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
09/03/20243:30PMGlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Your Recent History

Delayed Upgrade Clock